FDA updates certain COVID-19 monoclonal antibody authorizations
The Food and Drug Administration Friday updated its emergency use authorizations for two intravenous infusion therapies for outpatients at risk for progressing to severe COVID-19 disease. Specifically, it updated the patient selection criteria and safety summary for the monoclonal antibodies bamlanivimab and etesevimab administered together, and the patient selection criteria for the monoclonal antibodies casirivimab with imdevimab (REGEN-CON) administered together. For details on the changes, see the FDA fact sheets for bamlanivimab and etesevimab and REGEN-COV.
Related News Articles
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…